# Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2025

- Company: [Amneal Pharmaceuticals, Inc.](/companies/amrx.md) (CIK 1723128)
- Form: 10-Q
- Filed: 2025-08-07
- Accepted by EDGAR: Aug 7, 2025, 16:10 ET
- Period: 2025-06-30
- Accession: 0001723128-25-000047
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000047/amrx-20250630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000047/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-04-01 to 2025-06-30 | $724.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2025-01-01 to 2025-06-30 | $1.42bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2025-04-01 to 2025-06-30 | $438.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2025-01-01 to 2025-06-30 | $877.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2025-04-01 to 2025-06-30 | $286.3m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2025-01-01 to 2025-06-30 | $542.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2025-04-01 to 2025-06-30 | $48.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2025-01-01 to 2025-06-30 | $88.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2025-04-01 to 2025-06-30 | $124.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2025-01-01 to 2025-06-30 | $242.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-04-01 to 2025-06-30 | $111.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2025-01-01 to 2025-06-30 | $211.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2025-04-01 to 2025-06-30 | $16.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2025-01-01 to 2025-06-30 | $29.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-04-01 to 2025-06-30 | $22.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2025-01-01 to 2025-06-30 | $34.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-04-01 to 2025-06-30 | $0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2025-01-01 to 2025-06-30 | $0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-04-01 to 2025-06-30 | $0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2025-01-01 to 2025-06-30 | $0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-04-01 to 2025-06-30 | 322,363,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2025-01-01 to 2025-06-30 | 323,171,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2025-01-01 to 2025-06-30 | $91.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2025-01-01 to 2025-06-30 | $36.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2025-06-30 | $71.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-06-30 | $1.58bn | us-gaap:AssetsCurrent |
| Total assets | at 2025-06-30 | $3.42bn | us-gaap:Assets |
| Current liabilities | at 2025-06-30 | $1.11bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2025-06-30 | $2.15bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2025-06-30 | $31.2m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2025-06-30 | −$112.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 37,846 characters.

Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States (“U.S.”), India, and Ireland.

The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under *Item 1A. Risk Factors* in our 2024 Annual Report on Form 10-K and under the heading *Cautionary Note Regarding Forward-Looking Statements* included elsewhere in this Quarterly Report on Form 10-Q.

The following discussion and analysis for the three and six months ended June 30, 2025 should also be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2024 included in our 2024 Annual Report on Form 10-K.

### Overview

We have three reportable segments: Affordable Medicines, Specialty, and AvKARE. Refer to *Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* in our 2024 Annual Report on Form 10-K for a description of our segments. During the fourth quarter of 2024, we changed the name of our Generics segment to “Affordable Medicines” to reflect the full product offering of the segment. The name change did not result in any change to the composition of our reportable segments and, therefore, did not result in any change to our historical results.

#### The Pharmaceutical Industry

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our 2024 Annual Report on Form 10-K, as supplemented by *Part II, Item 1A “Risk Factors”* of our subsequent Quarterly Reports on Form 10-Q.

#### Inflation

While it is difficult to accurately measure the impact of inflation, we do not currently expect a material impact related to inflation for the year ending December 31, 2025. Notwithstanding our estimates, rising inflationary pressures due to higher input costs, including higher material, transportation, tariff impacts on supply, labor and other costs, could exceed our expectations, which would further adversely impact our operating results in future periods.

#### Trade Policy and Tariffs

We are subject to certain trade and tariff requirements imposed by the U.S. and various foreign governments. The great majority of our net sales rely on finished dosage forms (“FDF”) or active pharmaceutical ingredients (“API”) produced in the U.S. or India. We have limited reliance on imports from Europe and China, and no reliance on imports from Mexico or Canada.

During 2025, President Trump has announced a number of tariff actions, and while there are currently no reciprocal tariffs on pharmaceutical products imported into the U.S., this can change at any moment. In addition, on April 14, 2025, the Department of Commerce Bureau of Industry and Security announced that it had initiated, as of April 1, 2025, a broad investigation under section 232 of the Trade Expansion Act to determine the effects on national security of imports of pharmaceuticals (i.e. FDF, API, key starting materials, derivatives, and medical countermeasures). This is currently an investigation into whether trade remedies such as tariffs should be imposed and covers both generic and brand products.

Given the global nature of pharmaceutical supply chains, any changes to historically prevailing tariff requirements could impact us and our industry (i.e., increase costs, product availability, and supply chain disruptions). The Company is closely monitoring these tariff and trade developments and will take actions to reduce or minimize any material negative impact.

#### One Big Beautiful Bill Act

On July 4, 2025, President Trump signed the One Big Beautiful Bill Act (“OBBBA”), which includes a broad range of tax reform provisions affecting businesses. The OBBBA includes numerous changes to existing tax law including, extending or making permanent certain business and international tax measures initially established under the 2017 Tax Cuts and Jobs Act, which were set to expire. Additionally, the OBBBA permanently eliminates the requirement to capitalize and amortize U.S.-based research and experimental expenditures over five years, making these expenditures fully deductible in the period incurred. The Company expects these provisions to result in a reduction of current income tax liabilities. The Company will continue to analyze the OBBBA and its impact on its financial statements and will reflect any impact in the period of enactment.

### Results of Operations

### Comparison of Three Months Ended June 30, 2025 to Three Months Ended June 30, 2024

### Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the three months ended June 30, 2025 and 2024 (in thousands):

|  | Three Months Ended June 30, 2025 | 2024 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $724,508 | $701,780 | $22,728 | 3.2% |
| Cost of goods sold | 438,255 | 451,833 | (13,578) | (3.0)% |
| **Gross profit** | 286,253 | 249,947 | 36,306 | 14.5% |
| Selling, general and administrative | 124,266 | 116,462 | 7,804 | 6.7% |
| Research and development | 47,964 | 36,054 | 11,910 | 33.0% |
| Intellectual property legal development expenses | 2,017 | 1,042 | 975 | 93.6% |
| Restructuring and other charges | 1,024 | 220 | 804 | nm |
| (Credit) charges related to legal matters, net | (390) | 699 | (1,089) | nm |
| **Operating income** | 111,372 | 95,470 | 15,902 | 16.7% |
| Total other expense, net | (59,661) | (75,065) | 15,404 | (20.5)% |
| Income before income taxes | 51,711 | 20,405 | 31,306 | nm |
| Provision for income taxes | 16,101 | 3,618 | 12,483 | nm |
| **Net income** | $35,610 | $16,787 | $18,823 | nm |

nm - not meaningful

#### Net Revenue

Net revenue for the three months ended June 30, 2025 increased 3.2% from the prior year period, primarily due to:

- Growth in our Affordable Medicines segment net revenue of $6.1 million, primarily due to new products launched in 2025 and 2024, which contributed $33.0 million of year-over-year growth, and strong volume growth, partially offset by price erosion.
- Growth in our Specialty segment net revenue of $24.0 million, primarily driven by increases of $11.2 million, $9.0 million and $3.7 million in sales of CREXONT®, RYTARY® and UNITHROID®, respectively, partially offset by a decline in our non-promoted products.
- Decline in our AvKARE segment net revenue of $7.4 million, primarily driven by a reduction in our low margin distribution sales partially offset by expansion of our government label channel from new product introductions.

#### Cost of Goods Sold and Gross Profit

Cost of goods sold decreased 3.0% for the three months ended June 30, 2025 as compared to the prior year period. The decrease in cost of goods sold was primarily due to manufacturing efficiencies, partially offset by increased amortization related to CREXONT®.

Gross profit as a percentage of net revenue increased to 39.5% for the three months ended June 30, 2025 from 35.6% in the prior year period primarily as a result of the factors noted above.

Selling, general, and administrative (“SG&A”) expenses for the three months ended June 30, 2025 increased 6.7% as compared to the prior year period, primarily due to increases in employee compensation and launch costs associated with CREXONT®.

#### Research and Development

Research and development (“R&D”) expenses for the three months ended June 30, 2025 increased 33.0% as compared to the prior year period, primarily due to increases in employee compensation, increase in project spend and increase in in-licensing and upfront milestone payments.

#### Total Other Expense, Net

Total other expense, net for the three months ended June 30, 2025 decreased 20.5% as compared to the prior year period. The decrease was primarily driven by a $9.0 million period-over-period decrease in the increase in tax receivable agreement liability and the favorable impact of foreign exchange, primarily from the Euro.

#### Provision For Income Taxes

For the three months ended June 30, 2025, our provision for income taxes and effective tax rate were $16.1 million and 31.1%, respectively, as compared to $3.6 million and 17.7%, respectively, for the three months ended June 30, 2024. The period-over-period changes in the provision for income taxes and effective tax rate primarily related to differences in jurisdictional mix of income, the utilization of net operating losses in the prior period and discrete items related to share-based compensation in the current period.

### Affordable Medicines

The following table sets forth results of operations for our Affordable Medicines segment for the three months ended June 30, 2025 and 2024 (in thousands):

|  | Three Months Ended June 30, 2025 | 2024 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $433,425 | $427,328 | $6,097 | 1.4% |
| Cost of goods sold | 252,646 | 260,903 | (8,257) | (3.2)% |
| **Gross profit** | 180,779 | 166,425 | 14,354 | 8.6% |
| Selling, general and administrative | 34,226 | 31,627 | 2,599 | 8.2% |
| Research and development | 41,899 | 31,703 | 10,196 | 32.2% |
| Intellectual property legal development expenses | 1,978 | 1,032 | 946 | 91.7% |
| Restructuring and other charges | 683 | 53 | 630 | nm |
| (Credit) charges related to legal matters, net | (390) | 699 | (1,089) | nm |
| **Operating income** | $102,383 | $101,311 | $1,072 | 1.1% |

nm - not meaningful

#### Net Revenue

Affordable Medicines net revenue for the three months ended June 30, 2025 increased 1.4% as compared to the prior year period, primarily due to new products launched in 2025 and 2024, which contributed $33.0 million of year-over-year growth, and strong volume growth, partially offset by price erosion.

#### Cost of Goods Sold and Gross Profit

Affordable Medicines cost of goods sold for the three months ended June 30, 2025 decreased 3.2% as compared to the prior year period, primarily due to manufacturing efficiencies and favorable product mix, partially offset by increased plant and freight costs.

Affordable Medicines gross profit as a percentage of net revenue increased to 41.7% for the three months ended June 30, 2025 from 38.9% in the prior year period primarily as a result of the factors noted above.

Affordable Medicines SG&A expense for the three months ended June 30, 2025 increased 8.2% as compared to the prior year period, primarily due to increases in employee compensation and shipping costs.

#### Research and Development

Affordable Medicines R&D expenses for the three months ended June 30, 2025 increased 32.2% as compared to the prior year period, primarily due to increases in employee compensation, increase in project spend and increase in in-licensing and upfront milestone payments.

### Specialty

The following table sets forth results of operations for our Specialty segment for the three months ended June 30, 2025 and 2024 (in thousands):

|  | Three Months Ended June 30, 2025 | 2024 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $128,043 | $104,041 | $24,002 | 23.1% |
| Cost of goods sold | 55,795 | 46,142 | 9,653 | 20.9% |
| **Gross profit** | 72,248 | 57,899 | 14,349 | 24.8% |
| Selling, general and administrative | 30,314 | 26,610 | 3,704 | 13.9% |
| Research and development | 6,065 | 4,351 | 1,714 | 39.4% |
| Intellectual property legal development expenses | 39 | 10 | 29 | nm |
| Restructuring and other charges | 341 | 78 | 263 | nm |
| **Operating income** | $35,489 | $26,850 | $8,639 | 32.2% |

nm - not meaningful

#### Net Revenue

Specialty net revenue for the three months ended June 30, 2025 increased 23.1% compared to the prior year period, primarily driven by increases of $11.2 million, $9.0 million and $3.7 million in sales of CREXONT®, RYTARY® and UNITHROID®, respectively, partially offset by a decline in our non-promoted products.

#### Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the three months ended June 30, 2025 increased 20.9% compared to the prior year period, primarily due to increases in amortization related to CREXONT® and sales volume.

Specialty gross profit as a percentage of net revenue increased to 56.4% for the three months ended June 30, 2025 as compared to 55.7% in the prior year period due to the impact of increased amortization related to CREXONT®.

Specialty SG&A expense for the three months ended June 30, 2025 increased 13.9% as compared to the prior year period, primarily due to launch costs associated with CREXONT® and increases in employee compensation.

#### Research and Development

Specialty R&D expense for the three months ended June 30, 2025 increased 39.4% as compared to the prior year period, primarily due to higher project spend.

### AvKARE

The following table sets forth results of operations for our AvKARE segment for the three months ended June 30, 2025 and 2024 (in thousands):

|  | Three Months Ended June 30, 2025 | 2024 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $163,040 | $170,411 | $(7,371) | (4.3)% |
| Cost of goods sold | 129,814 | 144,788 | (14,974) | (10.3)% |
| **Gross profit** | 33,226 | 25,623 | 7,603 | 29.7% |
| Selling, general and administrative | 15,079 | 14,642 | 437 | 3.0% |
| **Operating income** | $18,147 | $10,981 | $7,166 | 65.3% |

#### Net Revenue

AvKARE net revenue for the three months ended June 30, 2025 decreased 4.3% as compared to the prior year period, primarily driven by a reduction in our low margin distribution sales partially offset by expansion of our government label channel from new product introductions.

#### Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the three months ended June 30, 2025 decreased 10.3% as compared to the prior year period, primarily due to a reduction of sales in our low margin distribution channel partially offset by higher sales in our government label channel.

Gross profit as a percentage of net revenue increased to 20.4% for the three months ended June 30, 2025 from 15.0% in the prior year period, primarily as a result of the factors noted above.

#### Selling, General and Administrative

AvKARE SG&A expense for the three months ended June 30, 2025 increased 3.0% as compared to the prior year period, primarily due to increases in employee compensation and freight costs.

### Comparison of Six Months Ended June 30, 2025 to Six Months Ended June 30, 2024

### Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the six months ended June 30, 2025 and 2024 (in thousands):

|  | Six Months Ended June 30, 2025 | 2024 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $1,419,928 | $1,360,971 | $58,957 | 4.3% |
| Cost of goods sold | 877,784 | 872,964 | 4,820 | 0.6% |
| **Gross profit** | 542,144 | 488,007 | 54,137 | 11.1% |
| Selling, general and administrative | 242,554 | 229,057 | 13,497 | 5.9% |
| Research and development | 88,004 | 75,352 | 12,652 | 16.8% |
| Intellectual property legal development expenses | 3,784 | 2,026 | 1,758 | 86.8% |
| Restructuring and other charges | 1,595 | 1,690 | (95) | (5.6)% |
| (Credit) charges related to legal matters, net | (390) | 95,058 | (95,448) | (100.4)% |
| Other operating (income) expense | (5,122) | 100 | (5,222) | nm |
| **Operating income** | 211,719 | 84,724 | 126,995 | nm |
| Total other expense, net | (122,522) | (139,841) | 17,319 | (12.4)% |
| Income (loss) before income taxes | 89,197 | (55,117) | 144,314 | nm |
| Provision for income taxes | 28,969 | 9,774 | 19,195 | nm |
| **Net income (loss)** | $60,228 | $(64,891) | $125,119 | nm |

nm - not meaningful

#### Net Revenue

Net revenue for the six months ended June 30, 2025 increased 4.3% from the prior year period primarily due to:

- Growth in our Affordable Medicines segment net revenue of $29.5 million, primarily due to new products launched in 2025 and 2024, which contributed $73.8 million of year-over-year growth, and strong volume growth, partially offset by price erosion.
- Growth in our Specialty segment net revenue of $27.1 million, primarily driven by increases of $20.3 million, $3.9 million and $7.7 million in sales of CREXONT®, RYTARY® and UNITHROID®, respectively, partially offset by a decline in our non-promoted products. In addition, the prior year period included $4.5 million of out-licensing revenue associated with IPX203.
- Growth in our AvKARE segment net revenue of $2.4 million, primarily driven by growth in our government label channel resulting from new product introductions, partially offset by a decline in our lower margin distribution channel.

#### Cost of Goods Sold and Gross Profit

Cost of goods sold for the six months ended June 30, 2025 was relatively flat compared to the prior year period, as increased amortization related to CREXONT® and increased plant and freight costs, partially offset by manufacturing efficiencies and a decline of sales in our lower margin distribution channel.

Gross profit as a percentage of net revenue increased to 38.2% for the six months ended June 30, 2025 from 35.9% in the prior year period, primarily as a result of the factors noted above.

SG&A expenses for the six months ended June 30, 2025 increased 5.9% as compared to the prior year period, primarily due to increases in employee compensation and launch costs associated with CREXONT®, partially offset by a reduction in legal expenses primarily resulting from insurance coverage for certain legal fees.

#### Research and Development

R&D expenses for the six months ended June 30, 2025 increased 16.8% as compared to the prior year period, primarily due to increases in employee compensation, increase in project spend and increase in in-licensing and upfront milestone payments.

#### (Credit) charges Related to Legal Matters, Net

For the six months ended June 30, 2024, charges related to legal matters, net of $95.1 million were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against us by political subdivisions and Native American tribes across the U.S. Refer to *Note 16. Commitments and Contingencies* for additional information.

#### Other Operating Income

Other operating income for the six months ended June 30, 2025 was comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector (the “PLI Scheme”).

#### Total Other Expense, Net

Total other expense, net for the six months ended June 30, 2025 decreased 12.4% as compared to the prior year period. The decrease was primarily driven by a $9.4 million decrease in interest expense as a result of lower rates and lower amounts outstanding on our variable-rate debt and the favorable impact of foreign exchange, primarily from the Euro.

#### Provision For Income Taxes

For the six months ended June 30, 2025, our provision for income taxes and effective tax rate were $29.0 million and 32.5%, respectively, as compared to $9.8 million and (17.7)%, respectively, for the six months ended June 30, 2024. The period-over-period changes in the provision for income taxes and effective tax rate primarily related to differences in jurisdictional mix of income, the utilization of net operating losses in the prior period and discrete items related to share-based compensation in the current period.

### Affordable Medicines

The following table sets forth results of operations for our Affordable Medicines segment for the six months ended June 30, 2025 and 2024 (in thousands):

|  | Six Months Ended June 30, 2025 | 2024 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $848,133 | $818,622 | $29,511 | 3.6% |
| Cost of goods sold | 495,279 | 500,825 | (5,546) | (1.1)% |
| **Gross profit** | 352,854 | 317,797 | 35,057 | 11.0% |
| Selling, general and administrative | 67,941 | 64,712 | 3,229 | 5.0% |
| Research and development | 72,879 | 66,074 | 6,805 | 10.3% |
| Intellectual property legal development expenses | 3,691 | 1,992 | 1,699 | 85.3% |
| Restructuring and other charges | 683 | 53 | 630 | nm |
| Charges related to legal matters, net | (390) | 95,058 | (95,448) | (100.4)% |
| Other operating income | (5,122) | — | (5,122) | nm |
| **Operating income** | $213,172 | $89,908 | $123,264 | nm |

nm - not meaningful

#### Net Revenue

Affordable Medicines net revenue for the six months ended June 30, 2025 increased 3.6% as compared to the prior year period, primarily due to new products launched in 2025 and 2024, which contributed $73.8 million of year-over-year growth, and strong volume growth, partially offset by price erosion.

#### Cost of Goods Sold and Gross Profit

Affordable Medicines cost of goods sold for the six months ended June 30, 2025 decreased 1.1% as compared to the prior year period, primarily due to manufacturing efficiencies and favorable product mix, partially offset by increased plant and freight costs.

Affordable Medicines gross profit as a percentage of net revenue increased to 41.6% for the six months ended June 30, 2025 from 38.8% in the prior year period, primarily as a result of the factors noted above.

Affordable Medicines SG&A expense for the six months ended June 30, 2025 increased 5.0% as compared to the prior year period, primarily due to increases in employee compensation and shipping costs.

#### Research and Development

Affordable Medicines R&D expenses for the six months ended June 30, 2025 increased 10.3% as compared to the prior year period, primarily due to increases in employee compensation and increase in in-licensing and upfront milestone payments.

#### Charges Related to Legal Matters, Net

For the six months ended June 30, 2024, charges related to legal matters, net of $95.1 million were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against us by political subdivisions and Native American tribes across the U.S. Refer to *Note 16. Commitments and Contingencies* for additional information.

#### Other Operating Income

Other operating income for the six months ended June 30, 2025 was comprised of income earned from the PLI Scheme.

### Specialty

The following table sets forth results of operations for our Specialty segment for the six months ended June 30, 2025 and 2024 (in thousands):

|  | Six Months Ended June 30, 2025 | 2024 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $236,340 | $209,275 | $27,065 | 12.9% |
| Cost of goods sold | 108,878 | 90,942 | 17,936 | 19.7% |
| **Gross profit** | 127,462 | 118,333 | 9,129 | 7.7% |
| Selling, general and administrative | 61,292 | 51,806 | 9,486 | 18.3% |
| Research and development | 15,125 | 9,278 | 5,847 | 63.0% |
| Intellectual property legal development expenses | 93 | 34 | 59 | nm |
| Restructuring and other charges | 471 | 1,024 | (553) | (54.0)% |
| Other operating expense | — | 100 | (100) | nm |
| **Operating income** | $50,481 | $56,091 | $(5,610) | (10.0)% |

nm - not meaningful

#### Net Revenue

Specialty net revenue for the six months ended June 30, 2025 increased 12.9% as compared to the prior year period, primarily driven by increases of $20.3 million, $3.9 million and $7.7 million in sales of CREXONT®, RYTARY® and UNITHROID®, respectively, partially offset by a decline in our non-promoted products. In addition, the prior year period included $4.5 million of out-licensing revenue associated with IPX203.

#### Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the six months ended June 30, 2025 increased 19.7% as compared to the prior year period, primarily due to increases in amortization related to CREXONT® and sales volume.

Specialty gross profit as a percentage of net revenue decreased to 53.9% for the six months ended June 30, 2025 as compared to 56.5% in the prior year period due to the impact of increased amortization related to CREXONT®.

Specialty SG&A expense for the six months ended June 30, 2025 increased 18.3% as compared to the prior year period, primarily due to launch costs associated with CREXONT® and increases in employee compensation.

#### Research and Development

Specialty R&D expenses for the six months ended June 30, 2025 increased 63.0% as compared to the prior year period, primarily due to increased in-licensing and upfront milestone payments of $3.0 million and higher project spend.

### AvKARE

The following table sets forth results of operations for our AvKARE segment for the six months ended June 30, 2025 and 2024 (in thousands):

|  | Six Months Ended June 30, 2025 | 2024 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $335,455 | $333,074 | $2,381 | 0.7% |
| Cost of goods sold | 273,627 | 281,197 | (7,570) | (2.7)% |
| **Gross profit** | 61,828 | 51,877 | 9,951 | 19.2% |
| Selling, general and administrative | 30,773 | 29,549 | 1,224 | 4.1% |
| **Operating income** | $31,055 | $22,328 | $8,727 | 39.1% |

#### Net Revenue

AvKARE net revenue for the six months ended June 30, 2025 increased 0.7% as compared to the prior year period primarily driven by growth in our government label channel resulting from new product introductions, partially offset by a decline in our lower margin distribution channel.

#### Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the six months ended June 30, 2025 decreased 2.7% as compared to the prior year period primarily due to a reduction of sales in our low margin distribution channel partially offset by higher sales in our government label channel and an increase in the inventory provision.

Gross profit as a percentage of net revenue increased to 18.4% for the six months ended June 30, 2025 from 15.6% in the prior year period, primarily as a result of the factors noted above.

#### Selling, General and Administrative

AvKARE SG&A expense for the six months ended June 30, 2025 increased 4.1% as compared to the prior year period, primarily due to increases in employee compensation and shipping costs.

### Liquidity and Capital Resources

Our primary source of liquidity is cash generated from operations, available cash on hand, and borrowings under debt financing arrangements (as defined and discussed in *Note 15. Debt* in our 2024 Annual Report on Form 10-K). On April 9, 2025, the Company executed an amendment to the Amended Rondo Revolving Credit Facility that, among other things, (i) increased the aggregate revolving commitment from $70 million to $125 million, (ii) increased the letter of credit commitment from $60 million to $90 million, and (iii) extended the maturity to April 9, 2030. As of June 30, 2025, we had access to $304.7 million of available capacity under the Amended New Revolving Credit Facility and $83.0 million of available capacity under the Amended Rondo Revolving Credit Facility. We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations, including acquisitions, and provide sufficient liquidity over the next 12 months from the date of filing of this Quarterly Report on Form 10-Q. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions, the impact of international trade policy, including tariffs, our ability to negotiate and maintain satisfactory terms under our borrowing and debt facilities in the future, and demand for our products, which are factors that may be out of our control. Our primary uses of capital resources are to fund operating activities, including R&D expenses associated with new product filings, and pharmaceutical product manufacturing expenses, license payments, spending on production facility expansions, capital equipment, acquisitions, and legal settlements.

We estimate that we will invest approximately $120.0 million during 2025 for capital expenditures to support and grow our existing operations, primarily related to investments in manufacturing equipment, information technology, and facilities. Our 2025 estimate includes capital expenditures for our collaboration and supply agreement with Metsera, Inc. (“Metsera”), of which we expect Metsera to reimburse us approximately $20.0 million. We expect such reimbursements to primarily be included in our cash flows from financing activities.

#### Debt Instruments

Over the next 12 months, we expect to make substantial payments, including monthly interest and quarterly principal amounts due for our Term Loan Due 2028, monthly interest on our Amended New Credit Facility, and contractual payments for leased premises. Refer to *Note 12. Debt* in this Quarterly Report on Form 10-Q and *Note 15. Debt, Note 17. Leases,* and *Commitments and Contractual Obligations under Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* in our 2024 Annual Report on Form 10-K for additional information.

#### Settlement in Principle on Nationwide Civil Prescription Opioid Litigation

In late April 2024, we reached a nationwide settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases that have been filed and that might have been filed by Attorneys General, political subdivisions and Native American tribes. Refer to *Note 16. Commitments and Contingencies* and *Note 21. Subsequent Events* for additional information.

#### Tax Receivable Agreement

As part of the Reorganization (as defined in *Note 1. Nature of Operations* in our 2024 Annual Report on Form 10-K), the tax receivable agreement (“TRA”) was amended to reduce our future obligation to pay 85% of the realized tax benefits subject to the TRA to 75% of such realized benefits. As of June 30, 2025, the contingent TRA liability, including the impact of the amendment, was approximately $118.7 million. During the six months ended June 30, 2025, the Company made payments of $3.0 million, associated with the TRA.

The timing and amount of any payments under the TRA may vary, depending upon a number of factors including the timing and amount of our taxable income, and the corporate tax rate in effect at the time of realization of our taxable income. The timing and amount of payments may also be accelerated under certain conditions, such as a change of control or other early termination event, which could give rise to our obligation to make TRA payments in advance of tax benefits being realized. For further information, including our recognized current and long-term liabilities for the TRA, refer to *Note 4. Income Taxes* in this Quarterly Report on Form 10-Q and *Item 1A. Risk Factors* and *Note 6. Income Taxes* in our 2024 Annual Report on Form 10-K.

#### Tax-Related Distributions

In 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”). The sellers of AvKARE, LLC and R&S (the “AvKARE Sellers”) hold the remaining 34.9% interest in the holding company that directly owns the acquired companies (“Rondo”). We attribute 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. During the six months ended June 30, 2025 and 2024, we made cash distributions of $25.0 million and $8.9 million, respectively, to the AvKARE Sellers. During July 2025, we made cash tax distributions of $6.0 million to the AvKARE Sellers.

#### AvKARE Excess Cash Distribution

On July 31, 2025, we made a $7.0 million cash distribution to the AvKARE Sellers from excess cash on hand.

#### Refinancing

On August 1, 2025, Amneal issued $600 million aggregate principal amount of 6.875% senior secured notes due 2032 (the “Senior Notes Due 2032”) at par in a private offering. Concurrently with the offering of the Senior Notes Due 2032, Amneal borrowed $2.1 billion aggregate principal amount of new seven-year term loans (the “Term Loans Due 2032”) under a new term loan facility, and used the net proceeds of the Term Loans Due 2032 and the Senior Notes Due 2032 to refinance its existing Term Loan Due 2028 in full, repay outstanding amounts borrowed under its Amended New Revolving Credit Facility and to pay related fees, premiums and expenses.

Interest is payable on the Term Loans Due 2032 at a rate equal to the term SOFR benchmark rate or the base rate, plus an applicable margin, in each case, subject to a term SOFR benchmark rate floor of 0.50% or a base rate floor of 1.00%, as applicable. The applicable margin for the Term Loans Due 2032 is 3.50% per annum for term SOFR benchmark rate loans and 2.50% per annum for base rate loans.

In addition, Amneal entered into a second amendment to the Amended New Revolving Credit Facility which extends the maturity to August 1, 2030.

#### Cash Balances

As of June 30, 2025, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the U.S. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

### Cash Flows

The following table sets forth our summarized, consolidated cash flows for the six months ended June 30, 2025 and 2024 (in thousands):

| Net cash provided by (used in): | Six Months Ended June 30, 2025 | 2024 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Operating activities | $91,227 | $35,247 | $55,980 | 158.8% |
| Investing activities | (44,345) | (26,225) | (18,120) | 69.1% |
| Financing activities | (80,853) | (58,241) | (22,612) | 38.8% |
| Effect of exchange rate changes on cash | (777) | (266) | (511) | 192.1% |
| Net decrease in cash, cash equivalents, and restricted cash | $(34,748) | $(49,485) | $14,737 | (29.8)% |

#### Cash Flows from Operating Activities

Net cash provided by operating activities was $91.2 million for the six months ended June 30, 2025 as compared to $35.2 million in the prior year period. The period-over-period increase was primarily driven by the payment of $52.4 million associated with the Opana ER® antitrust litigation settlement during the six months ended June 30, 2024. Excluding the Opana ER® antitrust litigation settlement payment, net cash provided by operating activities were relatively flat period-over-period.

#### Cash Flows from Investing Activities

Net cash used in investing activities for the six months ended June 30, 2025 was $44.3 million as compared to $26.2 million in the prior year period. The period-over-period increase in net cash used in investing activities was primarily due to an increase in higher capital expenditures, partially offset by a decrease in acquired intangible assets primarily driven by the payment of a sales-based milestone related to a licensing and supply agreement in the prior year period.

#### Cash Flows from Financing Activities

Net cash used in financing activities was $80.9 million for the six months ended June 30, 2025 as compared to $58.2 million in the prior year period. The period-over-period increase in net cash used in financing activities was primarily due to increases in employee payroll tax withholding on restricted stock unit and performance stock unit vesting and tax and other distributions to non-controlling interests, partially offset by payments on the Sellers Notes in the prior year period.

### Commitments and Contractual Obligations

Our contractual obligations are set forth in *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* contained in our 2024 Annual Report on Form 10-K. As of June 30, 2025, there have been no material changes to the disclosure presented in our 2024 Annual Report on Form 10-K.

### Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of June 30, 2025.

### Critical Accounting Policies and Estimates

For a discussion of our critical accounting policies and estimates, see *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* in our 2024 Annual Report on Form 10-K. There have been no material changes to the disclosures presented in our 2024 Annual Report on Form 10-K.

### Recently Issued Accounting Standards

Recently issued accounting standards are discussed in *Note 1. Summary of Significant Accounting Policies.*

## Market risk

As filed, 198 characters.

There has not been any material change in our assessment of market risk as set forth in *Item 7A. Quantitative and Qualitative Disclosures About Market Risk*, in our 2024 Annual Report on Form 10-K.

## Controls and procedures

As filed, 2,875 characters.

### Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2025.

### Changes in Internal Control over Financial Reporting

During the quarter ended June 30, 2025, there were no changes in our internal control over financial reporting which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on the Effectiveness of Controls

Management, including our Co-Chief Executive Officers and Chief Financial Officer, does not expect that our disclosure controls and procedures or our system of internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed or operated, can provide only reasonable, but not absolute, assurance that the objectives of the system of internal control are met. The design of our control system reflects the fact that there are resource constraints, and that the benefits of such control system must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control failures and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the intentional acts of individuals, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part on certain assumptions about the likelihood of future events, and there can be no assurance that the design of any particular control will always succeed in achieving its objective under all potential future conditions.

## Risk factors

As filed, 134 characters.

There have been no material changes to the disclosures presented in our 2024 Annual Report on Form 10-K under *Item 1A. Risk Factors.*

Filed Aug 7, 2025.
Source: SEC EDGAR, the filing index for accession 0001723128-25-000047. Last ingested by Listed: Nov 10, 2026, 02:45 ET. No prices; not investment advice.
